Skip to search.
 TSX Down 0.67% TSX Ventures Up 0.03%

Celgene Corporation (CELG)

-NasdaqGS
109.43 Down 1.14(1.03%) Sep 23, 4:00PM EDT
|After Hours : 109.43 0.00 (0.00%) Sep 23, 6:02PM EDT
Prev Close:110.57
Open:110.87
Bid:109.01 x 200
Ask:109.79 x 200
1y Target Est:137.30
Beta:1.4671
Earnings Date:Nov 3 - Nov 7 (Est.)
Day's Range:109.29 - 111.14
52wk Range:93.05 - 128.39
Volume:3,071,064
Avg Vol (3m):4,281,100
Market Cap:84.82B
P/E (ttm):46.25
EPS (ttm):2.37
Div & Yield:N/A (N/A)
Quotes delayed, except where indicated otherwise. Currency in USD.

Comparison

Symbol% ChgMkt Cap
CELGDown 1.03%84.82B
JNJDown 0.54%325.05B

Key Statistics

Forward P/E (1 yr):15.66
P/S (ttm):8.43
Ex-Dividend Date:N/A

Analysts

Annual EPS Est (Dec-16) :5.71
Quarterly EPS Est (Sep-16) :1.48
Mean Recommendation*:1.8
PEG Ratio (5 yr expected):0.89

* (Strong Buy) 1.0 - 5.0 (Sell)

Analyst Opinion | Estimates

Business Summary

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell ly... View More
Your browser doesn't support canvas
SETTINGS
Scrolling
Speed
Display
Price
Submit Feedback